Intellegens: Developing a novel ML-driven tool to advance Oligonucleotide-therapeutic characterisation and manufacturing.

Intellegens:开发一种新颖的机器学习驱动工具来推进寡核苷酸治疗的表征和制造。

基本信息

  • 批准号:
    10063439
  • 负责人:
  • 金额:
    $ 184.8万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Collaborative R&D
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

Intellegens Ltd is seeking to develop a novel ML-powered digital tool to provide organisations with a user interface for oligonucleotide characterisation and impurity prediction. Intellegens will collaborate with the Centre for Process Innovation (CPI) to build an extensive database of associated structures and intelligent look-up logic defined and coded into the software to create specific profiles for target molecules.Nucleic Acid Therapies (NATs) is a major emerging new class of medicines, offering enormous potential to treat a range of common and rare diseases with typically reduced timescales for development that can be quicker than other classes of drugs. In addition, NATs provide opportunities to tailor treatments to individual patients based on their genome sequence. However, the broader clinical application of NATs can be limited by current methods of manufacture and delivery.Oligonucleotides are segmented into several classes, including antisense, ribozymes, aptamers, miRNA, CPG/Immunostimulatory and RNAi. Many therapeutic areas and indications are currently targeted by oligo therapies from oncology (29%), Central Nervous System (CNS) disorders (12%) and genetic disorders (9%) to cardiovascular, respiratory, ophthalmology, gastrointestinal and infectious diseases. The global oligonucleotide development pipeline currently has 660 in preclinical, 70 phase-1, 94 phase-2, 19 phase-3 and 13 marketed, with a larger proportion targeting patient populations \>500k. 40% of approvals have occurred within 5-years (e.g. Inclisiran), providing a positive signal/confidence that oligonucleotides are a valid therapeutic area \[NICE,2021\]. This is encouraging more investment at the discovery end.Impurity prediction tools designed for small molecules are not sophisticated enough to predict impurities for oligonucleotides. With improved mechanistic understanding and screening approaches, more potent oligo candidates with better safety profiles can be identified for treatment of an increasing range of diseases and patient populations. The recent surge in approved oligonucleotide therapeutics indicates imminent potential as oligos are of intermediate size with much-improved selectivity towards the target and fewer off-target effects than small molecules \[Thakur,2022\].Intellegens addresses the unmet market need for a digital tool capable of impurity prediction and characterisation of the large and complex nature of oligonucleotides. Subsequently, reducing development costs and facilitating manufacturing scale-up.
IntelLegens Ltd正在寻求开发一种基于ML的新型数字工具,为组织提供用于寡核苷酸表征和杂质预测的用户界面。IntelLegens将与过程创新中心(CPI)合作,建立一个广泛的相关结构和智能查找逻辑的数据库,并将其定义并编码到软件中,以创建目标分子的特定配置文件。核酸疗法(NAT)是一种主要的新兴药物类别,具有治疗一系列常见和罕见疾病的巨大潜力,开发时间通常比其他类别的药物更快。此外,NAT提供了根据患者的基因组序列为他们量身定做治疗方案的机会。然而,NAT的广泛临床应用受到目前制造和递送方法的限制。寡核苷酸分为几类,包括反义、核酶、适体、miRNA、CpG/免疫刺激和RNAi。目前,许多治疗领域和适应症都是寡头疗法的目标,从肿瘤(29%)、中枢神经系统(CNS)疾病(12%)和遗传性疾病(9%)到心血管、呼吸系统、眼科、胃肠道和传染病。全球寡核苷酸开发流水线目前有660个处于临床前,70个1期,94个2期,19个3期和13个上市,其中更大比例的目标是患者群体。40%的批准发生在5年内(例如Inclisiran),这提供了一个积极的信号/信心,即寡核苷酸是一个有效的治疗领域\[NICE,2021\]。这鼓励了在发现端进行更多的投资。为小分子设计的杂质预测工具还不够复杂,不足以预测寡核苷酸的杂质。有了更好的机械性理解和筛选方法,可以确定更有效的、安全性更好的寡核苷酸候选药物,用于治疗越来越多的疾病和患者群体。最近批准的寡核苷酸疗法的激增表明了迫在眉睫的潜力,因为寡聚分子是中等大小的,对靶标的选择性大大提高,并且比小分子[塔库尔,2022]更少的偏离靶标的影响。IntelLegens解决了对能够预测和表征寡核苷酸的大而复杂性质的数字工具的未满足的市场需求。随后,降低开发成本,促进制造规模扩大。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

其他文献

吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
生命分子工学・海洋生命工学研究室
生物分子工程/海洋生物技术实验室
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:

的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('', 18)}}的其他基金

An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
  • 批准号:
    2901954
  • 财政年份:
    2028
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
  • 批准号:
    2896097
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
  • 批准号:
    2780268
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
  • 批准号:
    2908918
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
  • 批准号:
    2908693
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
  • 批准号:
    2908917
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
  • 批准号:
    2879438
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
  • 批准号:
    2890513
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
  • 批准号:
    2879865
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
  • 批准号:
    2876993
  • 财政年份:
    2027
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Studentship

相似海外基金

Towards sustainable cultured meat production by developing a novel biocatalyst
通过开发新型生物催化剂实现可持续的培养肉生产
  • 批准号:
    BB/Y007859/1
  • 财政年份:
    2024
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Research Grant
Developing a new generation of tools for predicting novel AMR mutation profiles using generative AI
使用生成人工智能开发新一代工具来预测新型 AMR 突变谱
  • 批准号:
    BB/Z514305/1
  • 财政年份:
    2024
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Research Grant
Collaborative Research: DMREF: Developing and Harnessing the Platform of Quasi-One-Dimensional Topological Materials for Novel Functionalities and Devices
合作研究:DMREF:开发和利用用于新功能和器件的准一维拓扑材料平台
  • 批准号:
    2324033
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Standard Grant
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
  • 批准号:
    495592
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
Developing novel, potent, and brain permeable inhibitors of inosine monophosphate dehydrogenase to prevent brain metastases
开发新型、有效且脑可渗透的肌苷单磷酸脱氢酶抑制剂以预防脑转移
  • 批准号:
    496426
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Fellowship Programs
Developing a novel Climate change Risk Assessment Framework for cultural heritage in Turkey (CRAFT)- Phase II
为土耳其文化遗产制定新颖的气候变化风险评估框架(CRAFT)-第二阶段
  • 批准号:
    AH/X006816/1
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Research Grant
Cicero - Developing chickpea as a novel source of domestic UK protein
西塞罗 - 将鹰嘴豆开发为英国国内蛋白质的新来源
  • 批准号:
    10052996
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Collaborative R&D
HoloMem: Developing a novel holographic data storage technology to address the growing need within global data storage
HoloMem:开发一种新颖的全息数据存储技术,以满足全球数据存储日益增长的需求
  • 批准号:
    10049468
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Collaborative R&D
Developing and testing a novel self-guided digital therapeutic solution for preventing stammering in children: incorporating latest research on early detection and progress evaluation using real-world data
开发和测试一种新颖的自我引导数字治疗解决方案,用于预防儿童口吃:结合使用真实世界数据进行早期检测和进展评估的最新研究
  • 批准号:
    10072187
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Collaborative R&D
Developing Novel Technology for Data Driven Clinical Decision Making
开发数据驱动临床决策的新技术
  • 批准号:
    MR/Y007816/1
  • 财政年份:
    2023
  • 资助金额:
    $ 184.8万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了